Compare TORO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | NKTX |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 198.2M |
| IPO Year | 2022 | 2020 |
| Metric | TORO | NKTX |
|---|---|---|
| Price | $6.42 | $2.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 19.9K | ★ 523.4K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.81 | $1.70 |
| 52 Week High | $8.50 | $3.72 |
| Indicator | TORO | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 60.23 |
| Support Level | $4.87 | $2.59 |
| Resistance Level | $6.49 | $3.29 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 88.81 | 62.43 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.